Clinical Trials Logo

Clinical Trial Summary

The CaveoVasc Thrombolysis Protection System is intended to aid sheath access and reduce bleeding complications during catheter directed thrombolysis (CDT) in the treatment of limb ischemia. This device has been designed to protect the puncture site by stabilizing the CDT sheath with the double-balloons that are part of the CaveoVasc system. Also the device is designed to reduce bleeding at the puncture site during CDT.

This study is designed to assess the safety and performance of the CaveoVasc Thrombolysis Protection System in twenty patients with limb ischemia undergoing treatment with CDT.


Clinical Trial Description

Catheter directed thrombolysis (CDT) is a non-surgical option for many patients, which involves the insertion of an infusion catheter (via the femoral artery) into the thrombus allowing for slow delivery of a pharmacological thrombolytic agent. Insertion of the infusion catheter is performed in the catheterization laboratory. The patient is usually then transferred to the intensive care unit, with delivery catheter in place and the infusion running for at least 24 hours.

The major complications reported with CDT include major and minor bleeding, and complications secondary to early termination of the CDT due to access site bleeding.

CaveoMed developed the CaveoVasc® Thrombolysis Protection System, a vascular access protection device intended for use in thrombolysis procedures. Its function is to facilitate sheath access, and minimize risks of access site bleeding complications during lengthy catheter-directed thrombolysis procedures. Pressure balloons inflated outside the artery maintain a good seal throughout thrombolysis, which typically lasts up to 24 hours. The thrombolysis catheter is then removed, and hemostasis at the site is managed per the hospital's standard.

The CaveoVasc® Thrombolysis Protection System design has important advantages for use during CDT procedures (which require long catheter dwell times). The system is intended to protect from intra-procedural bleeding at the arterial access site, which currently remains a major problem for patients with critical limb ischemia undergoing CDT treatment. This protection would lower the rate of bleeding events, and increase the rate of completed intended therapy, without interruption of the CDT treatment due to bleeding complications. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03166059
Study type Interventional
Source CaveoMed GmbH
Contact
Status Not yet recruiting
Phase N/A
Start date January 2018
Completion date February 2018

See also
  Status Clinical Trial Phase
Completed NCT03104062 - Effect of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients With Acute Myocardial Infarction N/A
Completed NCT04925869 - Prospective Study of Cerebrovascular Accidents (CVA) in 3 French Cities (Besançon, Cayenne and Tours)
Recruiting NCT03901872 - Contemporary Endovascular Therapies in Treatment of Acute Iliofemoral Deep Vein Thrombosis
Completed NCT03785678 - Tenecteplase in Stroke Patients Between 4.5 and 24 Hours Phase 3
Recruiting NCT05424978 - Application of Standardized Green Channel Treatment System for Ischemic Stroke in Xi 'an
Completed NCT02576379 - The Impact of a Helicopter Emergency Medical System on Prognosis in Stroke Patients N/A
Recruiting NCT06149520 - A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis Phase 2
Recruiting NCT02926742 - Submassive Pulmonary Embolism Experience With EKOS N/A
Recruiting NCT06221371 - Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion Phase 3
Active, not recruiting NCT01665885 - Hypothermia in Acute Ischemic Stroke - Surface Versus Endovascular Cooling (HAIS-SE) Phase 2